A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Beckman Symposium Bookmark and Share

The 23rd Beckman Symposium - Antibody Engineering

Date
Friday, December 6, 2013
8:30 a.m. to 5 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 23rd Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2013 Speaker List:
 
Patrick A. Baeuerle, Ph.D.
Amgen Research, Munich, Germany
 
Shmuel Cabilly, Ph.D.
High Tech Investor and Board Member
 
Paul Carter, Ph.D.
Genentech
 
Herbert A. Heynecker, Ph.D.
Advisor, Thuja Capital
 
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
 
Arthur D. Riggs, Ph.D.
City of Hope
 
Peter Senter, Ph.D.
Seattle Genetics, Inc.
 
E. Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
 
Anna Wu, Ph.D.
University of California, Los Angeles

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

2013 Symposium Program

8:30 to 9 a.m.
Registration
 

9 to 9:10 a.m.
Welcome
David Horne, Ph.D.
Interim Director, Beckman Research Institute
City of Hope
 
9:10 to 9:20 a.m.
Overview of Morning Session
John E. Shively, Ph.D.
City of Hope
 
9:20 to 10:10 a.m.
Early Recombinant Antibody Studies at City of Hope and Genentech
Arthur D. Riggs, Ph.D., City of Hope
Shmuel Cabilly, Ph.D., High Tech Investor and
Board Member Herbert Heynecker, Ph.D., Advisor, Thuja Capital
 
10:10 to 10:30 a.m.
Break
 
10:30 to 11:20 a.m.
Engineered Antibodies for Molecular Imaging in Oncology and Beyond
Anna Wu, Ph.D., University of California
Los Angeles
 
11:20 a.m. to 12:10 p.m.
From Knobs-into-Holes to Onartuzumab
Paul Carter, Ph.D., Genentech
 
12:10 to 1:10 p.m.
Lunch
 
1:10 to 1:20 p.m.
Overview of Afternoon Session
Andrew Raubitschek, M.D.
City of Hope
 
1:20 to 2:10 p.m.
Combinatorial and Evolutionary Engineering:
The Binders and Targets
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
 
2:10 to 3 p.m.
Targeting FcRn for Therapy
Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
 
3 to 3:20 p.m.
Break
 
3:20 to 4:10 p.m.
Empowered Antibodies for Cancer Therapy
Peter Senter, Ph.D.
Seattle Genetics, Inc.
 
4:10 to 5 p.m.
Cancer Therapy by T Cell-engaging
Bispecific Antibodies
Patrick Baeuerle, Ph.D., Amgen Research,
Munich, Germany

Registration

*Registration and lunches are limited to the first 350 registrants*
 

Beckman Symposium

The 23rd Beckman Symposium - Antibody Engineering

Date
Friday, December 6, 2013
8:30 a.m. to 5 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 23rd Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2013 Speaker List:
 
Patrick A. Baeuerle, Ph.D.
Amgen Research, Munich, Germany
 
Shmuel Cabilly, Ph.D.
High Tech Investor and Board Member
 
Paul Carter, Ph.D.
Genentech
 
Herbert A. Heynecker, Ph.D.
Advisor, Thuja Capital
 
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
 
Arthur D. Riggs, Ph.D.
City of Hope
 
Peter Senter, Ph.D.
Seattle Genetics, Inc.
 
E. Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
 
Anna Wu, Ph.D.
University of California, Los Angeles

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

Symposium Program

2013 Symposium Program

8:30 to 9 a.m.
Registration
 

9 to 9:10 a.m.
Welcome
David Horne, Ph.D.
Interim Director, Beckman Research Institute
City of Hope
 
9:10 to 9:20 a.m.
Overview of Morning Session
John E. Shively, Ph.D.
City of Hope
 
9:20 to 10:10 a.m.
Early Recombinant Antibody Studies at City of Hope and Genentech
Arthur D. Riggs, Ph.D., City of Hope
Shmuel Cabilly, Ph.D., High Tech Investor and
Board Member Herbert Heynecker, Ph.D., Advisor, Thuja Capital
 
10:10 to 10:30 a.m.
Break
 
10:30 to 11:20 a.m.
Engineered Antibodies for Molecular Imaging in Oncology and Beyond
Anna Wu, Ph.D., University of California
Los Angeles
 
11:20 a.m. to 12:10 p.m.
From Knobs-into-Holes to Onartuzumab
Paul Carter, Ph.D., Genentech
 
12:10 to 1:10 p.m.
Lunch
 
1:10 to 1:20 p.m.
Overview of Afternoon Session
Andrew Raubitschek, M.D.
City of Hope
 
1:20 to 2:10 p.m.
Combinatorial and Evolutionary Engineering:
The Binders and Targets
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
 
2:10 to 3 p.m.
Targeting FcRn for Therapy
Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
 
3 to 3:20 p.m.
Break
 
3:20 to 4:10 p.m.
Empowered Antibodies for Cancer Therapy
Peter Senter, Ph.D.
Seattle Genetics, Inc.
 
4:10 to 5 p.m.
Cancer Therapy by T Cell-engaging
Bispecific Antibodies
Patrick Baeuerle, Ph.D., Amgen Research,
Munich, Germany

Registration

Registration

*Registration and lunches are limited to the first 350 registrants*
 
Research Overview
Research pioneered at City of Hope has improved the lives of men, women and children throughout the world.
 
Beckman Research Institute

Beckman Research Institute of City of Hope is internationally  recognized for its innovative translational biomedical research.
 

Comprehensive Cancer Center
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and education.

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Technology & Licensing
The Center for Applied Technology Development offers broad expertise in
technology transfer and licensing, biologics manufacturing, quality assurance and regulatory affairs.

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

NEWS & UPDATES
  • Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is...
  • Brain tumor removal would seem to be the obvious course of action in the wake of a brain tumor diagnosis, but that’s not always the case. Some tumors are too difficult for many surgeons to reach or too close to areas that control vital functions. Removing them just proves too risky. A new device being con...
  • Hijacking the same sorts of viruses that cause HIV and using them to reprogram immune cells to fight cancer sounds like stuff of the future. Some scientists believe that the future is closer than we think – and are now studying the approach in clinical trials at City of Hope. Immunotherapy is a promising approa...
  • Nausea is the one of the most well-known, and dreaded, side effects of cancer treatment — and with good reason. Beyond the quality-of-life issues that it causes, severe nausea can prevent patients from receiving enough nutrients and calories at a time when they need every edge they can get. A few simple actions...
  • With Labor Day just around the corner, summer is on its way out. But just because summertime is ending doesn’t mean we can skip sunscreen. Protection from ultraviolet (UV) radiation is needed all year round. Exposure to UV radiation — whether from the sun or from artificial sources such as sunlamps used i...
  • Undergoing reconstructive surgery may seem like a forgone conclusion for survivors of breast cancer, but that doesn’t appear to be the case. A new study has found that most breast cancer survivors who undergo a mastectomy decide against surgical reconstruction of their breasts. The reasons for such a deci...
  • Nearly four decades ago, City of Hope began its bone marrow transplant program. Its first transplant reunion celebration was a single patient and his donor, also his brother. This year, City of Hope welcomed hundreds of hematopoietic cell transplant (HCT) recipients to the annual bone marrow transplant/HCT reun...
  • The burgeoning type 2 diabetes epidemic casts a pall over the health of America’s public. New research now shows the looming threat is getting worse. Much worse. A diabetes trends study published earlier this month in the Lancet Diabetes and Endocrinology by researchers at the federal Centers for Disease Contro...
  • An aspirin a day might help keep breast cancer away for some breast cancer survivors, a new study suggests. Obese women who have had breast cancer could cut their risk of a recurrence in half if they regularly take aspirin or other nonsteroidal anti-inflammatory drugs, called NSAIDs, report researchers from the...
  • Christine Crews isn’t only a fitness enthusiast, she’s also a personal trainer and fitness instructor. Being active defines her life. So when she was diagnosed with bladder cancer at age 30, she decided she absolutely couldn’t let the disease interfere with that lifestyle. And it didn’t. For t...
  • Cancer treatment and the cancer itself can cause changes in your sense of taste or smell. These side effects typically subside after treatment ends, but there are ways to help alleviate those bitter and metallic tastes in your mouth. Here are tips from the National Cancer Institute to help keeps tastes and food...
  • Immunotherapy — using one’s immune system to treat a disease — has been long lauded as the “magic bullet” of cancer treatments, one that can be more effective than the conventional therapies of surgery, radiation or chemotherapy. One specific type of immunotherapy, called adoptive T cell thera...
  • Today, when cancer spreads from its original site to other parts of the body, a process known as metastasis, patients face an uphill battle. Treatments are poorly effective, and cures are nearly impossible. Further, incidence rates for these types of cancers are increasing – particularly for cancers that have s...
  • Thanks to the California Institute for Regenerative Medicine (CIRM), high school students across the state gained valuable hands-on experience with stem cell research this summer. City of Hope hosted eight of those students. As part of the CIRM Creativity Awards program, the young scholars worked full time as m...
  • Radiation therapy can help cure many children facing Hodgkin lymphoma and other cancers. When the radiation is delivered to a girl’s chest, however, it can lead to a marked increase in breast cancer risk later in life. A recent multi-institutional study that included City of Hope’s Smita Bhatia, M.D., M.P.H., t...